Evidence map›Paper›PMID 39509846›Full record

Trial reportEuropean journal of cancer (Oxford, England : 1990)2024

Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.

Lingyun Sun, Yun Xu, Nan Chen, Chunze Zhang, Aiwen Wu, Huaqing Wang, Yutong Fei, Peng Shu, Dechang Diao, Jianping Cheng and 22 more

Abstract readRandomized Controlled TrialMulticenter StudyClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of cancer (Oxford, England : 1990), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Lingyun SunXiyuan Hospital, China Academy of Chinese Medical Sciences, China. Electronic address: slyslysun@126.com.
Yun XuXiyuan Hospital, China Academy of Chinese Medical Sciences, China.
Nan ChenBeijing Cancer Hospital, China.
Chunze ZhangTianjin People's Hospital, China.
Aiwen WuBeijing Cancer Hospital, China.
Huaqing WangTianjin People's Hospital, China.
Yutong FeiBeijing University of Chinese Medicine, China.
Peng ShuJaingsu Provincial TCM Hospital, China.
Dechang DiaoGuangdong TCM Hospital, China.
Jianping ChengBeijing Civil Aviation General Hospital, China.
Yuping ChuBeijing ChaoYang Hospital, China.
Tianshu LiuZhongshan Hospital of Fudan University, China.
Wei WangChongqing Cancer Hospital, China.
Ye YuanChangzhou People's Hospital, China.
Baozhu ZengZhengzhou TCM Hospital, China.
Yang CaoZhengzhou Third People's Hospital, China.
Shundong CangHenan People's Hospital, China.
Huijuan CaoBeijing University of Chinese Medicine, China.
Tong ZhangXiyuan Hospital, China Academy of Chinese Medical Sciences, China.
Yang ZhengTianjin People's Hospital, China.
Cun'en WuJaingsu Provincial TCM Hospital, China.
Shaoyong LiuBeijing ChaoYang Hospital, China.
Bin HeXiyuan Hospital, China Academy of Chinese Medical Sciences, China.
Yunzi YanBeijing University of Chinese Medicine, China.
Shaohua YanDongfang Hospital Affiliated to Beijing University of Chinese Medicine, China.
Na WuThe Affiliated Hospital of Hunan Academy of Traditional Chinese Medcine, China.
Chunhui NingXiyuan Hospital, China Academy of Chinese Medical Sciences, China.
Rongyan PengBeijing University of Chinese Medicine, China.
Andrew S EpsteinMemorial Sloan Kettering Cancer Center, USA.
Samuel CytrynMemorial Sloan Kettering Cancer Center, USA.
Jun J MaoMemorial Sloan Kettering Cancer Center, USA. Electronic address: maoj@mskcc.org.
Yufei YangXiyuan Hospital, China Academy of Chinese Medical Sciences, China. Electronic address: yyf93@vip.sina.com.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

purposeMany cancer patients express interest in using herbal medicine during chemotherapy, but little is known about its benefits and risks. This study aimed to evaluate the effects of the Chinese herbal medicine JianPi-BuShen formula (JPBS) on adjuvant chemotherapy completion in colon cancer patients. PATIENTS AND

methodsThis multi-center, phase III, randomized, placebo-controlled trial included patients with stage II (high risk for recurrence) and stage III colon cancer following surgery, planning to receive CAPOX (capecitabine and oxaliplatin) chemotherapy. Patients were randomized 1:1 to receive either JPBS or a placebo. The primary outcome was the completion rate of planned chemotherapy cycles. Secondary outcomes included relative dose intensity (RDI), chemotherapy-induced toxicities, quality of life (measured by the Edmonton Symptom Assessment System - ESAS), adverse events (AEs), and serious AEs (SAEs). Predefined subgroup analyses were performed by age (>65/≤65) and TNM stage (II/III).

resultsA total of 376 participants were analyzed, with a median age of 60.3 years; 56.9 % were male, and 67.6 % had stage III disease. Chemotherapy completion was significantly higher in the JPBS group than in the placebo group (63.0 % vs. 47.6 %, P = 0.003). Oxaliplatin RDI was also higher in the JPBS group (P = 0.049). Subgroup analyses showed JPBS significantly improved completion rates for stage II patients (73.0 % vs. 42.4 %, P = 0.001) and younger patients (66.9 % vs. 48.8 %, P = 0.004). JPBS reduced grade ≥ 2 vomiting (3.8 % vs. 6.4 %, P = 0.007) but increased grade ≥ 2 thrombocytopenia (16.2 % vs. 12.4 %, P = 0.012). Quality of life improved in stage II and younger patients.

conclusionJPBS improved chemotherapy completion rates in stage II and younger colon cancer patients without compromising tolerability. Further research is needed to explore its mechanisms and long-term effects.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCapecitabineColonic NeoplasmsDrugs, Chinese HerbalNeoplasm StagingAdultAgedChemotherapy, AdjuvantFemaleHumansMaleMiddle AgedOxaliplatinQuality of LifeCapecitabineDrugs, Chinese HerbalOxaliplatinAdjuvant chemotherapyColon cancerCompletion rateRandomized controlled trialRelative dose intensityTraditional Chinese herbal medicine

Identifiers

PMID39509846
PMCPMC11622473

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.